Karyopharm Therapeutics Inc.
Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by inhibiting the nuclear export protein XPO1. Selinexor has shown single-agent and combination activity against a variety of cancers with multiple later phase clinical trials ongoing. KPT-8602, a second generation SINE™ compound, and KPT-9274, a dual PAK4/NAMPT inhibitor, are also in oncology development.